FIGURE 2.
Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. (a) Changes from baseline FEV1 at week 16 and week 52 and (b) changes relative to placebo throughout the study. LS: least square.